Vetrina Vetricare Renal Syrup 100ml for Dogs & Cats

VETERINARY USE — For use under veterinary supervision in dogs and cats with chronic kidney disease (CKD) and hyperphosphataemia. Administer at 1ml per 5kg body weight per day mixed with food or as directed by a licensed veterinarian. Long-term use requires regular veterinary monitoring of serum phosphorus, creatinine, BUN, and SDMA levels. Keep out of reach of children. Store in a cool, dry place; keep bottle tightly capped after use.

Vetrina Vetricare Renal Syrup for Dogs & Cats (100ml) — Lanthanum Carbonate 150mg/ml

Vetrina Vetricare Renal Syrup is a lanthanum carbonate-based oral intestinal phosphate binder for dogs and cats with chronic kidney disease (CKD) and associated hyperphosphataemia (elevated serum phosphorus). Each 1ml delivers Lanthanum Carbonate 150mg — a non-absorbable rare-earth metal salt that binds dietary inorganic phosphate in the gastrointestinal tract with high affinity and specificity, reducing intestinal phosphate absorption and lowering serum phosphorus levels. Vetricare Renal Syrup is non-aluminium and non-calcium — avoiding the risks of aluminium neurotoxicity and calcium-load-associated soft tissue mineralisation associated with older phosphate binder classes. Suitable for long-term use as part of a veterinary-managed CKD phosphorus management programme.

Composition

• Lanthanum Carbonate — 150mg per 1ml: Rare-earth metal carbonate salt; oral intestinal phosphate binder with high phosphate-binding affinity across a wide pH range (effective in both the acidic stomach and neutral small intestine environments); mechanism of action — lanthanum ions (La³⁺) released from lanthanum carbonate in the acidic gastric environment bind with high affinity to dietary inorganic phosphate (H₂PO₄⁻, HPO₄²⁻) in the gastrointestinal lumen, forming insoluble lanthanum phosphate (LaPO₄) and lanthanum hydroxyphosphate precipitates that cannot be absorbed through the intestinal epithelium; these insoluble phosphate complexes are excreted in the faeces, reducing the dietary phosphate available for intestinal absorption; reduction of intestinal phosphate absorption lowers serum inorganic phosphorus (Pi) levels; controlled serum phosphorus is critical in CKD management because hyperphosphataemia drives: (1) renal secondary hyperparathyroidism (renal sHPT) via phosphate-driven suppression of renal 1-alpha-hydroxylase activity, reducing calcitriol (1,25-dihydroxyvitamin D3) synthesis and triggering parathyroid gland PTH upregulation; (2) renal tubular and interstitial mineralisation, accelerating nephron loss and CKD progression; (3) systemic vascular and soft tissue mineralisation; (4) FGF-23 (fibroblast growth factor 23) upregulation — an independent cardiovascular risk factor in CKD; lanthanum carbonate is minimally absorbed from the GI tract (systemic lanthanum exposure is very low), is not nephrotoxic, and does not cause calcium loading (unlike calcium carbonate/acetate binders) or aluminium toxicity (unlike aluminium hydroxide binders); suitable for use across all IRIS CKD stages (2–4) where serum phosphorus exceeds target range
• Syrup base and excipients for palatability and ease of administration — confirm from Vetrina Vetricare Renal Syrup product label

Therapeutic Class

• Veterinary oral intestinal phosphate binder — lanthanum carbonate — CKD hyperphosphataemia management — serum phosphorus reduction — renal secondary hyperparathyroidism prevention — dogs and cats

Key Benefits

• Effective serum phosphorus reduction — lanthanum carbonate binds dietary phosphate in the GI lumen with high affinity across a wide pH range, reducing intestinal phosphate absorption and lowering serum Pi
• Non-aluminium formulation — no risk of aluminium neurotoxicity (encephalopathy, osteomalacia) associated with aluminium hydroxide phosphate binders, particularly important in CKD patients with reduced aluminium clearance
• Non-calcium formulation — no risk of positive calcium balance, hypercalcaemia, or calcium-load-driven vascular and soft tissue mineralisation associated with calcium carbonate and calcium acetate phosphate binders
• Slows CKD progression — phosphate control reduces nephron loss from renal tubular/interstitial mineralisation, reduces renal sHPT-driven PTH nephrotoxicity, and reduces FGF-23-driven cardiovascular and renal injury
• Palatable syrup formulation — highly palatable oral syrup for easy administration mixed with food; reduces dosing stress in cats and small dogs
• Long-term safe use — minimal systemic absorption of lanthanum; suitable for ongoing CKD phosphorus management under veterinary monitoring

Indications

• Chronic kidney disease (CKD) with hyperphosphataemia (elevated serum phosphorus) in dogs and cats — all IRIS CKD stages (2–4) where serum Pi exceeds IRIS target range for stage
• Reduction of dietary phosphate absorption and serum phosphorus levels as part of a veterinary CKD management plan (renal diet + phosphate binder + underlying cause management)
• Prevention and management of renal secondary hyperparathyroidism (renal sHPT) in CKD dogs and cats
• CKD progression slowing — phosphate management to reduce nephron loss from mineralisation and PTH-mediated renal injury

Dosage & Administration

• Dogs & Cats: 1ml per 5kg body weight per day
• Mix with food immediately before feeding; administer with meals to maximise phosphate-binding efficacy — lanthanum carbonate must be present in the GI tract simultaneously with dietary phosphate
• Or administer as directed by a licensed veterinarian
• Confirm dose adjustment based on serial serum phosphorus monitoring with your veterinarian

Monitoring

• Regular veterinary monitoring of serum phosphorus (target IRIS CKD stage-specific Pi range), creatinine, BUN, SDMA, and parathyroid hormone (PTH) is recommended during long-term use
• Dose adjustment based on serum phosphorus response — confirm with veterinarian

Safety Information

• For veterinary use under supervision — do not self-prescribe or adjust dose without veterinary guidance
• Lanthanum carbonate is minimally absorbed systemically; lanthanum accumulation in bone and liver has been reported with long-term human use but clinical significance in companion animals at veterinary doses requires confirmation from product label and veterinarian
• Not for use in animals with intestinal obstruction or severe GI disease — confirm from product label
• Keep out of reach of children; store in a cool, dry place; keep cap tightly closed after use